MUMBAI, INDIA
Lupin's generic sugammadex injection wins FDA approval and launches in the US
- Sponsor
- Lupin Limited $LUPIN.BO
- Drug
- sugammadex
- Indication
- reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults undergoing surgery
FDA approved Lupin's generic sugammadex injection for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults undergoing surgery, and Lupin launched the product commercially. Sugammadex is a selective relaxant-binding agent originally marketed as Merck's Bridion; multiple generics have entered the US market since 2023.
What this means
Sugammadex is an injectable drug that reverses the effects of certain muscle-relaxing medications used during surgery. The FDA has approved a new generic version from Lupin, which is now available for sale. This approval introduces competition that could potentially lower costs for hospitals and surgical centers.
Drug Watch — recent news on sugammadex
- Camber Specialty launches generic Bridion - drugstorenews.com
- Dr. Reddy's launches generic Sugammadex Injection in the US - Voice of Healthcare
- Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States - Yahoo Finance
- Dr Reddy's Launches Generic Bridion Injection in US - Medical Dialogues
- Dr. Reddy's Launches First Generic Version of Sugammadex Injection in the US Market - scanx.trade